hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.
hVIVO appoints Nominated Adviser and Joint Broker
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Amilia Stone
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
hVIVO plc announces a breakthrough in identifying biomarkers for respiratory infections, published in Nature Communications, advancing diagnostics and patient care.
hVIVO plc, a leader in human challenge trials, secures an £11.5M contract with a global pharma client to test an antiviral using its RSV model.
hVIVO plc, a leader in human challenge trials, announces positive results for Enanta Pharmaceuticals' RSV antiviral candidate EDP-323 in a recent study.